May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Pressure–Lowering Efficacy of Bimatoprost and Latanoprost: Effect of Baseline Mean Diurnal IOP
Author Affiliations & Notes
  • T.E. Bournias
    Ophthalmology, Northwestern University, Chicago, IL
  • C. Abraham
    Ophthalmology, Northwestern University, Chicago, IL
  • Footnotes
    Commercial Relationships  T.E. Bournias, Allergan, Inc. C, R; C. Abraham, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4503. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T.E. Bournias, C. Abraham; Pressure–Lowering Efficacy of Bimatoprost and Latanoprost: Effect of Baseline Mean Diurnal IOP . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4503.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Compare the pressure–lowering efficacy of bimatoprost and latanoprost in patients with open–angle glaucoma (OAG) or ocular hypertension (OHT) at various levels of baseline IOP. Methods: Post–hoc analysis of data from a previously reported 6–month comparison trial of bimatoprost and latanoprost (Noecker at al, AJO 2003;135:55–63). IOP was measured during 8 AM, 12 PM, and 4 PM at study visits at baseline, week 1, and months 1, 3, and 6. The present analysis evaluated the reduction in mean diurnal IOP in the subgroups of patients with baseline mean diurnal IOP (average of the 8 AM, 12 PM, and 4 PM measurements) in the ranges of <21 mm Hg, from >21 mm Hg to <25 mm Hg, and >25 mm Hg. Results: Baseline mean diurnal IOP in the study population ranged from 18.3 mm Hg to 34.7 mm Hg and was comparable between treatment groups. At the final study visit, bimatoprost provided significantly greater reductions in mean diurnal IOP than latanoprost for all patient subgroups regardless of the baseline IOP. 

Conclusions: Patients with mean diurnal IOP in the high normal range, as well as those with elevated IOP, had larger drops in IOP and reached lower pressures with bimatoprost than with latanoprost. Regardless of their initial pressure, OAG and OHT patients achieve significantly greater IOP lowering with bimatoprost.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure • lipids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×